If approved, Dupixent would be the first biologic medicine approved in the region to treat these patients. The European Commission's final decision on the dupixent application is expected in the coming months, Regeneron said.
Price: 310.67, Change: +5.59, Percent Change: +1.83
|--Analyst Actions: Imperial Capital Lifts Johnson Ou...|
|STAAR Surgical Company Receives US FDA Approval for ...|
|TUI Sees Boeing 737 MAX Grounding to Continue Underm...|
|Sector Update: Top Energy Stocks Mostly Trading Lowe...|
|Forex Update: USD Inches Lower Following CPI Print|